Shen Maurice Y F, Perreault Melissa L, Fan Theresa, George Susan R
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Pharmacol Biochem Behav. 2015 Jan;128:33-40. doi: 10.1016/j.pbb.2014.11.011. Epub 2014 Nov 13.
A role for the dopamine D1-D2 receptor heteromer in the regulation of reward and addiction-related processes has been previously implicated. In the present study, we examined the effects of D1-D2 heteromer stimulation by the agonist SKF 83959 and its disruption by a selective TAT-D1 peptide on amphetamine-induced locomotor sensitization, a behavioral model widely used to study the neuroadaptations associated with psychostimulant addiction. D1-D2 heteromer activation by SKF 83959 did not alter the acute locomotor effects of amphetamine but significantly inhibited amphetamine-induced locomotor responding across the 5day treatment regimen. In addition, a single injection of SKF 83959 was sufficient to abolish the expression of locomotor sensitization induced by a priming injection of amphetamine after a 72-hour withdrawal. Conversely, inhibition of D1-D2 heteromer activity by the TAT-D1 peptide enhanced subchronic amphetamine-induced locomotion and the expression of amphetamine locomotor sensitization. Treatment solely with the TAT-D1 disrupting peptide during the initial 5day treatment phase was sufficient to induce a sensitized locomotor phenotype in response to the priming injection of amphetamine. Together these findings demonstrate that the dopamine D1-D2 receptor heteromer exerts a tonic inhibitory control on neurobiological processes involved in sensitization to amphetamine, indicating that the dopamine D1-D2 receptor heteromer may be a novel molecular substrate in addiction processes involving psychostimulants.
此前已有研究表明多巴胺D1-D2受体异聚体在奖赏及成瘾相关过程的调节中发挥作用。在本研究中,我们检测了激动剂SKF 83959对D1-D2异聚体的刺激作用,以及选择性TAT-D1肽对其的破坏作用,二者对苯丙胺诱导的运动致敏的影响,运动致敏是一种广泛用于研究与精神兴奋剂成瘾相关的神经适应性的行为模型。SKF 83959对D1-D2异聚体的激活并未改变苯丙胺的急性运动效应,但在为期5天的治疗方案中显著抑制了苯丙胺诱导的运动反应。此外,单次注射SKF 83959足以消除在72小时戒断后由苯丙胺引发注射诱导的运动致敏的表达。相反,TAT-D1肽对D1-D2异聚体活性的抑制增强了亚慢性苯丙胺诱导的运动以及苯丙胺运动致敏的表达。在最初的5天治疗阶段仅用TAT-D1破坏肽进行治疗就足以诱导对苯丙胺引发注射产生的致敏运动表型。这些研究结果共同表明,多巴胺D1-D2受体异聚体对与苯丙胺致敏相关的神经生物学过程发挥着持续性抑制作用,这表明多巴胺D1-D2受体异聚体可能是涉及精神兴奋剂的成瘾过程中的一种新型分子底物。